Search
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalColesevelam is a bile acid sequestrant. … It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the
Telaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label]. … Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Synonyms: (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamideCategories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnLike semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class [A7866]. … These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting
Products: Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen, Ivor 3500 IE Anti-Xa/0,2 ml Injektionslösung in FertigspritzenLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDEThiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigational[A252827] Sodium thiosulfate is approved for the treatment of acute cyanide poisoning[L310,L43332,A252832] and it is frequently used in conjunction with sodium nitrite (a salt form of [nitrous acid]). … Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate.
Categories: Compounds used in a research, industrial, or household settingEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalefficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … [A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigationalDatopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol.